Aura Biosciences closes $299M public offering including full exercise of underwriters' option

Aura Biosciences completed a public offering raising approximately $299.4 million by selling over 46 million shares of common stock and pre-funded warrants. The offering included the full exercise of underwriters' option to purchase additional shares, priced at $6.00 per share. This capital raise supports Aura's development of precision therapies for solid tumors, including their lead candidate, bel-sar (AU-011), in late-stage trials for ocular melanoma and early development for other cancers. The funds will help advance clinical programs and company growth.